REGENXBIO Inc. Comprehensive Income
REGENXBIO Inc. (RGNX) reported Comprehensive Income of $22.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-06
- REGENXBIO Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was $22.70M.
- REGENXBIO Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$90.23M, a 1588.52% decline year-over-year.
- REGENXBIO Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$67.18M.
- REGENXBIO Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$61.84M.
- REGENXBIO Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$193.82M.
- REGENXBIO Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$223.41M.
- REGENXBIO Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$252.52M.
- REGENXBIO Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$293.15M, a 333.34% decline from fiscal 2021.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.70M 10-Q · filed 2026-08-06 | -$67.53M 10-Q · filed 2026-08-06 | -$134.71M derived: sum of 3 quarters · filed 2026-08-06 | -$196.56M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$90.23M 10-Q · filed 2026-05-14 | -$157.42M derived: sum of 2 quarters · filed 2026-05-14 | -$219.26M derived: sum of 3 quarters · filed 2026-05-14 | -$290.12M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$67.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$129.03M derived: sum of 2 quarters · filed 2026-03-05 | -$199.89M derived: sum of 3 quarters · filed 2026-08-06 | -$193.82M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$61.84M 10-Q · filed 2025-11-06 | -$132.70M derived: sum of 2 quarters · filed 2026-08-06 | -$126.64M 10-Q · filed 2025-11-06 | -$177.99M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$70.86M 10-Q · filed 2026-08-06 | -$64.80M 10-Q · filed 2026-08-06 | -$116.14M derived: sum of 3 quarters · filed 2026-08-06 | -$174.06M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $6.06M 10-Q · filed 2026-05-14 | -$45.28M derived: sum of 2 quarters · filed 2026-05-14 | -$103.20M derived: sum of 3 quarters · filed 2026-05-14 | -$155.22M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$51.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$109.26M derived: sum of 2 quarters · filed 2026-03-05 | -$161.28M derived: sum of 3 quarters · filed 2026-03-05 | -$223.41M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$57.91M 10-Q · filed 2025-11-06 | -$109.94M derived: sum of 2 quarters · filed 2025-11-06 | -$172.07M 10-Q · filed 2025-11-06 | -$231.97M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$52.03M 10-Q · filed 2025-08-07 | -$114.16M 10-Q · filed 2025-08-07 | -$174.06M derived: sum of 3 quarters · filed 2025-08-07 | -$233.24M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$62.13M 10-Q · filed 2025-05-12 | -$122.03M derived: sum of 2 quarters · filed 2025-05-12 | -$181.22M derived: sum of 3 quarters · filed 2025-05-12 | -$251.75M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$59.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$119.09M derived: sum of 2 quarters · filed 2025-03-13 | -$189.63M derived: sum of 3 quarters · filed 2025-03-13 | -$252.52M 10-K · filed 2025-03-13 |
| 2023-09-30 | -$59.18M 10-Q · filed 2024-11-06 | -$129.72M derived: sum of 2 quarters · filed 2024-11-06 | -$192.62M 10-Q · filed 2024-11-06 | -$249.70M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | -$70.54M 10-Q · filed 2024-08-01 | -$133.43M 10-Q · filed 2024-08-01 | -$190.51M derived: sum of 3 quarters · filed 2025-03-13 | -$269.49M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | -$62.90M 10-Q · filed 2024-05-08 | -$119.98M derived: sum of 2 quarters · filed 2025-03-13 | -$198.95M derived: sum of 3 quarters · filed 2025-03-13 | -$269.95M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | -$57.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$136.06M derived: sum of 2 quarters · filed 2025-03-13 | -$207.05M derived: sum of 3 quarters · filed 2025-03-13 | -$293.15M 10-K · filed 2025-03-13 |
| 2022-09-30 | -$78.98M 10-Q · filed 2023-11-08 | -$149.97M derived: sum of 2 quarters · filed 2023-11-08 | -$236.07M 10-Q · filed 2023-11-08 | $56.67M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$70.99M 10-Q · filed 2023-08-02 | -$157.10M 10-Q · filed 2023-08-02 | $135.64M derived: sum of 3 quarters · filed 2024-02-27 | $77.21M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$86.10M 10-Q · filed 2023-05-03 | $206.63M derived: sum of 2 quarters · filed 2024-02-27 | $148.20M derived: sum of 3 quarters · filed 2024-02-27 | $90.67M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $292.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $234.30M derived: sum of 2 quarters · filed 2024-02-27 | $176.78M derived: sum of 3 quarters · filed 2024-02-27 | $125.63M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$58.44M 10-Q · filed 2022-11-03 | -$115.96M derived: sum of 2 quarters · filed 2022-11-03 | -$167.11M 10-Q · filed 2022-11-03 | -$213.97M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$57.53M 10-Q · filed 2022-08-03 | -$108.67M 10-Q · filed 2022-08-03 | -$155.54M derived: sum of 3 quarters · filed 2023-02-28 | -$147.23M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$51.15M 10-Q · filed 2022-05-04 | -$98.01M derived: sum of 2 quarters · filed 2023-02-28 | -$89.71M derived: sum of 3 quarters · filed 2023-02-28 | -$122.14M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$46.86M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$38.56M derived: sum of 2 quarters · filed 2023-02-28 | -$70.99M derived: sum of 3 quarters · filed 2023-02-28 | -$111.81M 10-K · filed 2023-02-28 |
| 2020-09-30 | $8.30M 10-Q · filed 2021-11-02 | -$24.13M derived: sum of 2 quarters · filed 2021-11-02 | -$64.95M 10-Q · filed 2021-11-02 | -$91.57M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$32.43M 10-Q · filed 2021-08-09 | -$73.25M 10-Q · filed 2021-08-09 | -$99.88M derived: sum of 3 quarters · filed 2022-03-01 | -$134.57M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$40.82M 10-Q · filed 2021-05-05 | -$67.44M derived: sum of 2 quarters · filed 2022-03-01 | -$102.14M derived: sum of 3 quarters · filed 2022-03-01 | -$103.06M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$26.62M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$61.31M derived: sum of 2 quarters · filed 2022-03-01 | -$62.24M derived: sum of 3 quarters · filed 2022-03-01 | -$93.85M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$34.69M 10-Q · filed 2020-11-04 | -$35.62M derived: sum of 2 quarters · filed 2020-11-04 | -$67.23M 10-Q · filed 2020-11-04 | -$62.77M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$927.00K 10-Q · filed 2020-08-06 | -$32.53M 10-Q · filed 2020-08-06 | -$28.07M derived: sum of 3 quarters · filed 2021-03-01 | -$47.38M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$31.61M 10-Q · filed 2020-05-07 | -$27.15M derived: sum of 2 quarters · filed 2021-03-01 | -$46.45M derived: sum of 3 quarters · filed 2021-03-01 | -$35.73M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $4.46M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$14.85M derived: sum of 2 quarters · filed 2021-03-01 | -$4.12M derived: sum of 3 quarters · filed 2021-03-01 | $99.93M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$19.30M 10-Q · filed 2019-11-05 | -$8.58M derived: sum of 2 quarters · filed 2019-11-05 | $95.47M 10-Q · filed 2019-11-05 | $79.31M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $10.73M 10-Q · filed 2019-08-07 | $114.78M 10-Q · filed 2019-08-07 | $98.62M derived: sum of 3 quarters · filed 2020-02-26 | $78.01M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $104.05M 10-Q · filed 2019-05-07 | $87.89M derived: sum of 2 quarters · filed 2020-02-26 | $67.28M derived: sum of 3 quarters · filed 2020-02-26 | $52.73M derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | -$16.16M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | -$36.77M derived: sum of 2 quarters · filed 2020-02-26 | -$51.32M derived: sum of 3 quarters · filed 2020-02-26 | -$73.85M 10-K · filed 2020-02-26 |
| 2017-09-30 | -$20.61M 10-Q · filed 2018-11-07 | -$35.16M derived: sum of 2 quarters · filed 2018-11-07 | -$57.69M 10-Q · filed 2018-11-07 | -$78.19M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | -$14.55M 10-Q · filed 2018-08-08 | -$37.08M 10-Q · filed 2018-08-08 | -$57.57M derived: sum of 3 quarters · filed 2019-02-27 | -$75.39M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | -$22.53M 10-Q · filed 2018-05-08 | -$43.03M derived: sum of 2 quarters · filed 2019-02-27 | -$60.85M derived: sum of 3 quarters · filed 2019-02-27 | -$75.04M derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | -$20.49M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$38.32M derived: sum of 2 quarters · filed 2019-02-27 | -$52.51M derived: sum of 3 quarters · filed 2019-02-27 | -$62.28M 10-K · filed 2019-02-27 |
| 2016-09-30 | -$17.82M 10-Q · filed 2017-11-08 | -$32.01M derived: sum of 2 quarters · filed 2017-11-08 | -$41.79M 10-Q · filed 2017-11-08 | -$47.66M derived: sum of 4 quarters · filed 2018-03-06 |
| 2016-06-30 | -$14.19M 10-Q · filed 2017-08-08 | -$23.96M 10-Q · filed 2017-08-08 | -$29.83M derived: sum of 3 quarters · filed 2018-03-06 | -$37.19M derived: sum of 4 quarters · filed 2018-03-06 |
| 2016-03-31 | -$9.77M 10-Q · filed 2017-05-09 | -$15.64M derived: sum of 2 quarters · filed 2018-03-06 | -$23.00M derived: sum of 3 quarters · filed 2018-03-06 | -$29.29M derived: sum of 4 quarters · filed 2018-03-06 |
| 2015-12-31 | -$5.87M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | -$13.23M derived: sum of 2 quarters · filed 2018-03-06 | -$19.52M derived: sum of 3 quarters · filed 2018-03-06 | -$23.53M 10-K · filed 2018-03-06 |
| 2015-09-30 | -$7.36M 10-Q · filed 2016-11-09 | -$13.65M derived: sum of 2 quarters · filed 2016-11-09 | -$17.66M 10-Q · filed 2016-11-09 | -$20.00M derived: sum of 4 quarters · filed 2017-03-07 |
| 2015-06-30 | -$6.29M 10-Q · filed 2016-08-09 | -$10.30M 10-Q · filed 2016-08-09 | -$12.64M derived: sum of 3 quarters · filed 2017-03-07 | -$14.43M derived: sum of 4 quarters · filed 2017-03-07 |
| 2015-03-31 | -$4.01M 10-Q · filed 2016-05-05 | -$6.35M derived: sum of 2 quarters · filed 2017-03-07 | -$8.14M derived: sum of 3 quarters · filed 2017-03-07 | |
| 2014-12-31 | -$2.34M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-07 | -$4.13M derived: sum of 2 quarters · filed 2017-03-07 | -$4.00M 10-K · filed 2017-03-07 | |
| 2014-09-30 | -$1.79M 10-Q · filed 2015-11-05 | -$1.67M 10-Q · filed 2015-11-05 | ||
| 2013-12-31 | -$5.39M 10-K · filed 2016-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |